Asensus Surgical — Transenterix — JP Morgan Healthcare Conference 2018
22 slides from Asensus Surgical's conference presentation, Jan 8, 2018

Slide 1: TransEnterix
\ Exhibit 99.1 Fenctnterix:

Slide 2: JP Morgan Healthcare Conference, Todd M. Pope
Todd M. Pope President & CEO JP Morgan Healthcare Conference January 8, 2018

Slide 3: Forward Looking Statements
Forward Looking Statements This presentation includes statements relating to TransEnterix’s current regulatory and commercialization plans for our products, the Senhance™ Surgical Robotic System and the SurgiBot™ System. These statements and other statements regarding our future plans and goals cons

Slide 4: Commercial Stage Surgical Robotics Company
Commercial Stage Clinically validated in multiple procedures and sites Senhance FDA cleared and CE Marked Sales and distribution in place in US and EU Strong financial position Compelling Platform Technology Senhance Surgical Robot Robotic benefits with responsible economics Focus: Surgical Robotics

Slide 5: Value-based healthcare is forcing hospitals to find new ways
Value-based healthcare is forcing hospitals to find new ways to improve outcomes, efficiencies and talent retention.

Slide 6: Surgical Robotics Poised for Growth
Surgical Robotics Poised for Growth in 2023 in 2017 Robotic surgery is <10% of surgery today Largest opportunity is to convert laparoscopic procedures; not enabled by current options Must meet value-based healthcare criteria and build off laparoscopy (>60% of surgery) Source: Abdominal Surgical Robo

Slide 7: Robotic Surgery Landscape
Robotic Surgery Landscape 0.7 MM procedures EU & U.S. Historical Growth Drivers: Convert open surgeries to robotics Offset signficant per-procedure cost increase with length of stay benefit vs. open surgery Clinical and patient benefits have come from converting an open procedure to a minimally-inva

Slide 8: Future Growth Drivers: Convert laparoscopic surgeries to robotics
Future Growth Drivers: Convert laparoscopic surgeries to robotics Improve laparoscopy: designed for greater precision, efficiencies, safety, ergonomics Provide meaningful robotic benefits to laparoscopic surgery without significant per procedure cost increase Sources: TRXC Estimates and Millennium R

Slide 9: Need for Robotic System that Addresses the Laparoscopic Market
Need for Robotic System that Addresses the Laparoscopic Market Familiar motion and approach Completed learning curve Significant investments in laparoscopic ecosystem Laparoscopy is Widespread Limitations of Laparoscopy Reliance on assistant to control camera Challenging ergonomics Imprecise instrum

Slide 10: Senhance is Uniquely Positioned to Address Laparoscopic Market
Senhance is Uniquely Positioned to Address Laparoscopic Market Senhance Robotic Benefits Precision Ergonomics Advanced Instrument-ation Eye- sensing camera control

Slide 11: Senhance Surgery
©» SsenhanceSurgery a: am

Slide 12: Growing TransEnterix Patent Portfolio
Growing TransEnterix Patent Portfolio Issued Patents: 93 worldwide Includes 25 US issued Patent Applications: 92 worldwide Includes 54 pending US applications

Slide 13: Building Clinical Validation
Building Clinical Validation Imperial College, St. Mary’s, London, England C.H.U. ST Etienne, Saint-Etienne, France St. Marien-Krankenhaus, Siegen, Germany University Clinic Hamburg – Eppendorf (UKE), Hamburg, Germany Humanitas University, Milan, Italy Policlinico Gemelli, Rome, Italy Saitama Medica

Slide 14: Senhance Robotic Inguinal Hernia Repair
Senhance Robotic Inguinal Hernia Repair Left side, TAPP, Lateral and Medial Hernias Dr. Dietmar Stephan, St. Marien Krankenhaus Siegen, Germany Department of Minimally Invasive and Robotic Surgery Clinic of General Surgery, Chief Prof. Dr. F. Willeke

Slide 15: Senhance FDA Cleared and CE Marked
Senhance FDA Cleared and CE Marked First new entrant to abdominal robotics since 2000 Senhance received FDA clearance October 2017 Cleared for colorectal and gynecological laparoscopic surgery in US Indications cover 23 procedures Covers benign and oncologic treatments Initial market 1.5 million US

Slide 16: Delivering on Open Architecture Strategy
Delivering on Open Architecture Strategy Robotic Microlap Open Source Visualization Introducing the first robotic microlap 3mm system Enabling virtually scarless surgery Using robotic precision, tremor filtration and surgeon camera control with microlaparoscopy Leverage existing hospital visualizati

Slide 17: Articulating Instrumentation and platform expansions
Articulating Instrumen n platform expans ons for use ons | 4 | Based on ultrasonic energy Clinically and financially validated need: $2+ billion global business in surgical advanced energy instruments Increase degrees of freedom in surgical cases Minimize incision size with 5mm platform Source: Medt

Slide 18: Commercial Activity - US
Commercial Activity - US Sales resources 17 sales professionals Majority of 20 largest MSAs covered Established surgeon training center at the Institute for Surgical Advancement in Orlando Q3 ’17 Strong presence at major trade shows Sales activities First sale to Florida Hospital Orlando Q4 ’17 Anti

Slide 19: Commercial Activity - OUS
Commercial Activity - OUS Strong foundation established Direct sales team covering Germany, Italy, France, Benelux & UK Distributors and agents expand coverage to other markets Sales activities Italian sale Q3 ’16 German sale in Q1 ’17 Japan sale Q2 ’17 Taiwan sale Q3 ’17 CIS sale Q4 ‘17

Slide 20: SurgiBot Commercialization Update/Strategy
SurgiBot Commercialization Update/Strategy Enables TransEnterix to expand portfolio, increases cash, and develops partner relationship for China manufacturing and distribution Received minimum consideration of $29 million (cash, stock purchase and royalties) Retain rights for distribution and sales

Slide 21: Financial (unaudited)
Financial (unaudited) 2017 Revenue ~ $7.0 million 360% increase over 2016 December 31, 2017 Balance Sheet Highlights Cash & Restricted Cash ~ $97 million Debt ~ $14 million Common shares outstanding ~ 199 million

Slide 22: Key Priorities
Key Priorities 2017 Continued focus on commercialization efforts in CE Mark countries ✓ Continue to demonstrate clinical success across multiple specialties and procedures ✓ Obtain Senhance US 510(k) clearance by year end ✓ Prepare for U.S. launch with focused market development activities ✓ 2018 Co
Source: SEC EDGAR · 8-K filed Jan 8, 2018
More decks from Asensus Surgical Inc
Investor Presentation (June 2023)25 slides · Jun 5, 2023
Investor Day (February 2023)65 slides · Feb 21, 2023
40th Annual J.P. Morgan Healthcare Conference (January 2022)23 slides · Jan 13, 2022
Transenterix — Investor Day (February 2021)22 slides · Feb 23, 2021
TransEnterix — H.C. Wainwright 22nd Annual Global Investment Conference (September 2020)20 slides · Sep 15, 2020
TransEnterix — Q3 2019 Earnings Presentation25 slides · Nov 13, 2019